Kristopher Brown

Nov 13, 2024 | mondaq.com | David Chen |Huiya Wu |Kristopher Brown |Krystal J. Lin

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China's life sciences sector. See the first post in the series here. While the overall Chinese M&A market fluctuated from 2021 to 2023 due to the pandemic and other factors, the life sciences pharmaceutical and biotech market remained relatively stable. Though the number of deals dipped in 2022, in 2023, it quickly recovered to 2021 levels.

Nov 11, 2024 | jdsupra.com | Yoko Bian |Summer Lawson |Kristopher Brown

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s life sciences sector. See the first post in the series here. 2023 and 2024 (Through End of Q3) China Life Sciences (Pharmaceutical/Biotech) M&A Deal Highlights While the overall Chinese M&A market fluctuated from 2021 to 2023 due to the pandemic and other factors, the life sciences pharmaceutical and biotech market remained relatively stable.